19 hrs ago
Gilead Earnings Preview: Non-Sovaldi Sales Bogey May Be Unrealistic
Gilead Sciences, Inc. reports Q2 earnings tomorrow. Gilead is a biopharmaceutical company that develops and markets medicines for unmet needs.
U.S. senators ask Gilead to explain cost of Sovaldi hepatitis drug
Two members of the U.S. Senate Finance Committee, including Chairman Ron Wyden, on Friday asked Gilead Sciences Inc to defend the more than $80,000 cost of its breakthrough treatment for hepatitis C, citing the expense to federal healthcare programs.
Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms
Much has been made of Merck's $3.85B acquisition of Idenix. Guesses have been made as to the next hepatitis C acquisition.
AbbVie And Johnson & Johnson Were In A Bidding War For Idenix...
In the new generation of hepatitis C treatment regimens, drugs called nucleotide analogs, or "nucs," are the golden ticket.
Gilead Down On Merck Idenix Deal, But Little To Fear
Merck announced it would buy Idenix Pharmaceuticals today for $3.85 billion, or $24.50 per share.